Brief: Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002
11/02/2026 12:46
Feb 11 (Reuters) - Stoke Therapeutics Inc STOK.O: STOKE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF STK-002, A POTENTIAL DISEASE-MODIFYING MEDICINE FOR THE TREATMENT OF AUTOSOMAL DOMINANT OPTIC ATROPHY (ADOA) STOKE THERAPEUTICS INC: DOSE ESCALATION OF FIRST FOUR COHORTS WILL CONTINUE THROUGH 2026 AND EARLY 2027, PENDING SAFETY AND TOLERABILITY ASSESSMENTS Source text: ID:nBw993Jrra Further company coverage: STOK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Stoke Therapeutics
See all newsBrief: Stoke Therapeutics Announces Inducement Grants
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare
U.S. STOCKS ON THE MOVE-NetEase, Werewolf Therapeutics, JP Morgan
U.S. STOCKS ON THE MOVE-Ubiquiti, BJ's Wholesale, Arbutus
U.S. STOCKS ON THE MOVE-Gold miners, Ross Stores, Stoke Therapeutics